TACTICS demonstrated the effectiveness of the initial treatment with an anti-VEGF inhibitor, followed by selective TACE, for intermediate-stage HCC; it is thought to be a landmark trial in the field of TACE combination trials. This evidence concerns the gene VEGFA and hepatocellular carcinoma.